Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: Review and Italian experience

Clinical and Experimental Rheumatology

Volumn 29, Issue 4, 2011, Pages 728-735

  Rossini, Maurizio ^a   Di Munno, Ombretta ^b   Gatti, Davide ^a   Giannini, Sandro ^c   Minisola, Salvatore ^d   Varenna, Massimo ^e   Adami, Silvano ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Adherence; Bisphosphonates; Italy; Osteoporosis; Safety

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; IBANDRONIC ACID; NERIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; CASE FINDING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILY HISTORY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; ITALY; KIDNEY INJURY; NEPHROTOXICITY; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; GASTROINTESTINAL DISEASES; HUMANS; ITALY; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 80055071342     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. DELMAS PD: Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018-26.
2. OSTERBERG L, BLASCHKE T: Adherence to medication. N Engl J Med 2005; 353: 487-97.
3. CRAMER JA, ROY A, BURRELL A et al.: Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7.
4. VIK SA, MAXWELL CJ, HOGAN DB: Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 2004; 38: 303-12.
5. BECKER MH, MAIMAN LA: Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975; 13: 10-24.
6. HUYBRECHTS KF, ISHAK KJ, CARO JJ: Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38: 922-8.
7. SIRIS ES, SELBY PL, SAAG KG, BORGSTROM F, HERINGS RM, SILVERMAN SL: Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122: S3-13.
8. GALLAGHER AM, RIETBROCK S, OLSON M, VAN STAA TP: Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008; 23: 1569-75.
9. SIRIS ES, HARRIS ST, ROSEN CJ et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013-22.
10. KOTHAWALA P, BADAMGARAV E, RYU S, MILLER RM, HALBERT RJ: Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007; 82: 1493-501.
11. RECKER RR, GALLAGHER R, MACCOSBE PE: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-61.
12. RUSSELL RG, WATTS NB, EBETINO FH, ROGERS MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-59.
13. BLACK DM, DELMAS PD, EASTELL R et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
14. CHESNUT III CH, SKAG A, CHRISTIANSEN C et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.
15. ETTINGER MP, GALLAGHER R, MACCOSBE PE: Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006; 12: 522-8.
16. PENNING-VAN BEEST FJ, GOETTSCH WG, ERKENS JA, HERINGS RM: Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006; 28: 236-42.
17. ROSSINI M, BIANCHI G, DI MUNNO O et al.: Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006; 17: 914-21.
18. BINKLEY N, MARTENS MG, SILVERMAN SL et al.: Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. South Med J 2009; 102: 486-92.
19. BLUMENTALS WA, HARRIS ST, COLE RE, HUANG L, SILVERMAN SL: Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Ann Pharmacother 2009; 43: 577-85.
20. COTTE FE, FARDELLONE P, MERCIER F, GAUDIN AF, ROUX C: Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010; 21: 145-55.
21. GATTI D, ROSSINI M, VIAPIANA O et al.: Adherence to oral osteoporosis treatment in the italian clinical practice. Reumatismo 2010; 62 (Suppl.): 1-8.
22. AGENZIA ITALIANA DEL FARMACO. INFORMAZIONE, SPERIMENTAZIONE E RICERCA: Available from: http://www.agenziafarmaco.it/it/content/normativa-3
23. CRYER B, BAUER DC: Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002; 77: 1031-43.
24. HAMILTON B, MCCOY K, TAGGART H: Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003; 14: 259-62.
25. REGINSTER JY, ADAMI S, LAKATOS P et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654-61.
26. ROSSINI M, VIAPIANA O, GATTI D, ADAMI S: Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther 2009; 31: 1497-510.
27. LEWIECKI EM, BABBITT AM, PIZIAK VK, OZTURK ZE, BONE HG: Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008; 30: 605-21.
28. ZAMBON A, BAIO G, MAZZAGLIA G, MERLINO L, CORRAO G: Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. Pharmacoepidemiol Drug Saf 2008; 17: 260-9.
29. ETTINGER MP, FELSENBERG D, HARRIS ST et al.: Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol 2005; 32: 1968-74.
30. UVEF: Schede di Health Technology Assessment sui farmaci valutati dalla Commissione Terapeutica Regionale. Available from: http://www.uvef.it/web/?pag=schedeinformative-sui-farmaci.
31. RINGE JD, BODY JJ: A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. Clin Exp Rheumatol 2007; 25: 766-74.
32. CAULEY JA, BLACK D, BOONEN S et al.: Once-yearly zoledronic acid and days of disability, bed rest and back pain: randomised controlled Horizon pivotal fracture trial. J Bone Miner Res 2011; 26: 984-992.
33. NEVITT MC, THOMPSON DE, BLACK DM et al.: Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000; 160: 77-85.
34. ARMINGEAT T, BRONDINO R, PHAM T, LEGRÉ V, LAFFORGUE P: Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 2006; 17: 1659-65.
35. ROVETTA G, MONTEFORTE P, BALESTRA V: Intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res 2000; 26: 25-30.
36. ADAMI S, BHALLA AK, DORIZZI R et al.: The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326-31.
37. BERTOLDO F, PANCHERI S, ZENARI S et al.: Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 2010; 25: 447-54.
38. JAMAL SA, BAUER DC, ENSRUD KE et al.: Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22: 503-8.
39. MILLER PD, ROUX C, BOONEN S, BARTON IP, DUNLAP LE, BURGIO DE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20: 2105-15.
40. MILLER PD, WARD P, PFISTER T, LEIGH C, BODY JJ: Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Clin Exp Rheumatol 2008; 26: 1125-33.
41. BOONEN S, SELLMEYER DE, LIPPUNER K et al.: Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008; 74: 641-8.
42. MILLER PD: The kidney and bisphosphonates. Bone 2011; Epub ahead of print.
43. WEIDE R, KOPPLER H, ANTRAS L et al.: Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther 2010; 6: 31-5.
44. PERAZELLA MA, MARKOWITZ GS: Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385-93.
45. JACKSON GH: Renal safety of ibandronate. Oncologist 2005; 10 (Suppl. 1): 14-8.
46. PFISTER T, ATZPODIEN E, BAUSS F: The renal effects of minimally nephrotoxic doses of ibandronate following single and intermittent administration in rats. Toxicology 2003; 191: 159-67.
47. PFISTER T, ATZPODIEN E, BOHRMANN B, BAUSS F: Acute renal effects of intravenous bisphosphonates in the rat.. Basic Clin Pharmacol Toxicol 2005; 97: 374-81.
48. BERGNER R, HENRICH DM, HOFFMANN M et al.: Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 2007; 47: 942-50.
49. BODY JJ, PFISTER T, BAUSS F: Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005; 19 (Suppl.): 3-7.
50. COMMISSIONE TERAPEUTICA INTERAZIENDALE AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA DI VERONA: Comunicazione variazione prontuario 2 febbraio 2009. http://www.ospedaleuniverona.it/Istituzionale/Commissione- Terapeutica-Interaziendale/Comunicazioni/
51. RUGGIERO SL, DODSON TB, ASSAEL LA, LANDESBERG R, MARX RE, MEHROTRA B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate- related osteonecrosis of the jaws- 2009 update. J Oral Maxillofac Surg 2009; 67 (5 Suppl.): 2-12.
52. SILVERMAN SL, LANDESBERG R: Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009; 122 (2 Suppl.): S33-45.
53. ANDI, SIOMMMS: Raccomandazioni relative all'osteonecrosi della mascella-mandibola associata a terapia con bisfosfonati in pazienti con osteoporosi: documento di consenso. Available from: http://www.siommms.it/ B3P_Siommms/B3L_Portal_Resources/ Pubblico/Modules/Articoli/WF_ArticoliDettaglio.aspx?idarticolo=57.
54. SHANE E, BURR D, EBELING PR et al.: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Mineral Res 2010; 25: 2267-94.
55. ROSSINI M, PISCITELLI P, FITTO F et al.: Incidence and socioeconomic burden of hip fractures in Italy. Reumatismo 2005; 57: 95-100.
56. PISCITELLI P, IOLASCON G, GIMIGLIANO F et al.: Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int 2007; 18: 211-9.
57. PISCITELLI P, GIMIGLIANO F, GATTO S et al.: Hip fractures in Italy: 2000-2005 extension study. Osteoporos Int 2010; 21: 1323-30.
58. ROSSINI M, ALBERTI V, FLOR L et al.: Effect of oral vitamin D2 yearly bolus on hip fracture risk in elderly women: a community primary prevention study. Aging Clin Exp Res 2004; 16: 432-6.
59. ISAIA G, GIORGINO R, RINI GB, BEVILACQUA M, MAUGERI D, ADAMI S: Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 2003; 14: 577-82.
60. WHOCCMBD: WHO fracture risk assessment tool (FRAX). Available from: http://www.shef.ac.uk/FRAX/.
61. ADAMI S, BIANCHI G, BRANDI M et al.: Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clin Exp Rheumatol 2010; 28: 561-70
62. MINISTERO ITALIANO DELLA SALUTE: Decreto Del Presidente Del Consiglio Dei Ministri 5 Marzo 2007. Available from: http://www. edott.it/LeggiDecreti/2007/DECRETO-DELPRESIDENTE- DEL-CONSIGLIO-DEI-MINISTRI- 5-marzo-2007-Modifica-del-decretodel- Presidente-del-Consiglio-dei-Ministri- 29-novembre-2001-recante--Definizionedei- livelli-essenziali-di-1000.aspx?C=1.
63. HARRIS ST, REGINSTER JY, HARLEY C et al.: Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 2009; 44: 758-65.
64. ADAMI S, ISAIA G, LUISETTO G et al.: Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 2006; 21: 1565-70.
65. BARONE A, GIUSTI A, PIOLI G et al.: Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc 2007; 55: 752-7.
66. ADAMI S, GIANNINI S, BIANCHI G et al.: Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20: 239-44.
67. ISHIJIMA M, SAKAMOTO Y, YAMANAKA M et al.: Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 2009; 85: 398-404.
68. DELMAS PD, ADAMI S, STRUGALA C et al.: Intravenous ibandronate injections in postmenopausal women with osteoporosis: oneyear results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838-46.
69. EISMAN JA, CIVITELLI R, ADAMI S et al.: Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35: 488-97.
70. CHAPURLAT RD, PALERMO L, RAMSAY P, CUMMINGS SR: Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 2005; 16: 842-8.
71. BONE HG, HOSKING D, DEVOGELAER JP et al.: Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-99.
72. MELLSTROM DD, SORENSEN OH, GOEMAERE S, ROUX C, JOHNSON TD, CHINES AA: Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462-8.
73. BLACK DM, SCHWARTZ AV, ENSRUD KE et al.: Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-38.
74. SCHWARTZ AV, BAUER DC, CUMMINGS SR et al.: Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010; 25: 976-82.
75. GEUSENS P: Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 2009; 7: 12-7.